Stock analysts at Benchmark began coverage on shares of CytoMed Therapeutics (NASDAQ:GDTC – Get Free Report) in a report issued on Friday, Marketbeat reports. The firm set a “buy” rating and a $5.00 price target on the stock. Benchmark’s target price indicates a potential upside of 33.33% from the company’s previous close. CytoMed Therapeutics Stock […]